Source: FDA Update on Rare Breast Implant-Associated Type of Lymphoma
Lymphoma
CHOP to be Chopped?
Once the most common treatment for indolent non-Hodgkin’s Lymphoma, the combination chemotherapy known as CHOP is rapidly falling to the wayside in Germany – replaced by bendamustine (Treanda), frequently combined with rituximab (Rituxan), researchers reported here.
via New Combo Replaces CHOP for Lymphoma.
NOTE the commercial interests disclosures at the end of the original article.
Chronic HBV and Lymphoma Risk
Medical News: Chronic HBV Raises Lymphoma Risk – in Infectious Disease, Hepatitis from MedPage Today
Among individuals who were positive for hepatitis B surface antigen (HBsAg), the adjusted hazard ratio for non-Hodgkin’s lymphoma was 1.74 (95% CI 1.45 to 2.09, P<0.0001), compared with those who tested negative, according to Eric A. Engels, MD, of the National Cancer Institute in Rockville, Md., and colleagues.
lifeunderwriter.net 